Medtech Insight is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


GAO Report On 510(k) Program Calls For Regulations On 20 Device Types

This article was originally published in The Gray Sheet

Executive Summary

A long-awaited government report on the premarket review process for devices says FDA needs to decide "expeditiously" how to review 20 types of devices: through the stringent PMA approval process or through the less rigorous and faster 510(k) clearance process

You may also be interested in...

Risk Classification And The Device-Benefit Question: Cranial Electrotherapy Stimulators

Companies are suspicious of FDA motivations in the drawn-out reclassification process for cranial electrotherapy stimulators. But the case also underscores how the agency's efforts to place devices in the appropriate risk category turns not only on the perceived safety of a device, but evidence supporting its benefits and the types of evidence the agency is comfortable accepting.

FDA Calling For More PMAs Than 510(k)s In Final Set Of Preamendment Devices

“The Gray Sheet” reviewed CDRH’s proposed orders and final classification decisions on preamendment devices targeted by the 515 initiative. As of Aug. 5, FDA has proposed or finalized 14 PMAs, and proposed or finalized 10 products to be downclassified to class II with special controls.

FDA Oversight Of Medical Products Remains A "High-Risk" Concern For GAO

The Government Accountability Office is once again listing FDA's ability to ensure the safety and effectiveness of devices, drugs and other medical products on its roster of "high-risk" concerns.

Related Content


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts